Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT05424315
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05424315
-
- Other papers using this trial's data
- Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05424315. Randomized; quadruple masking; primary purpose prevention. Start 2021-10-01 (actual); primary completion 2022-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
- Acronym
- DACAMI
- Condition
- Anterior MI
- Intervention (Drug)
- Dapagliflozin 10mg
- Intervention (Drug)
- Glucose Tab
- Lead sponsor
- Omar Younis
- Collaborator
- Ain Shams University
Record details
- Record id
cardio:ct-nct05424315- Content hash
9242e3936902a22b72e4dd54942341f643bb683e151c2f9a74b7e75eb7cff320